Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dapagliflozin + voglibose
- Development stage
- Phase 1
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of two oral antidiabetic drugs, dapagliflozin and voglibose, used in the management of type 2 diabetes mellitus. **Dapagliflozin** is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces renal glucose reabsorption, thereby increasing glucose excretion in the urine. **Voglibose** is an α-glucosidase inhibitor that delays carbohydrate digestion and absorption in the intestine, attenuating postprandial blood glucose spikes. Both drugs act independently of insulin secretion and primarily aim to improve glycemic control. Studies in Japanese patients with type 2 diabetes showed that co-administration of dapagliflozin and voglibose does not require dose adjustment of either agent and is well-tolerated[1][2][4].
- Brand names
- dapagliflozin + voglibose
- Other names
- dapagliflozin + voglibose
02
Targets
SGLT2 (Sodium-glucose cotransporter protein subunit 2)Sucrase-Isomaltase
Beyond the preview
Go deeper on dapagliflozin + voglibose.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dapagliflozin + voglibose.